Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950103-25-014354
Filing Date
2025-11-05
Accepted
2025-11-05 16:14:56
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 13547
2 EXHIBIT A dp237001_exa.htm EX-99.A 11022
  Complete submission text file 0000950103-25-014354.txt   26351
Mailing Address 500 BOYLSTON STREET SUITE 1350 BOSTON MA 02116
Business Address 500 BOYLSTON STREET SUITE 1350 BOSTON MA 02116 617-655-6580
Vor Biopharma Inc. (Subject) CIK: 0001817229 (see all company filings)

EIN.: 811591163 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-92269 | Film No.: 251454182
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O MAPLES CORPORATE SERVICES LIMITED UGLAND HOUSE, PO BOX 309 GRAND CAYMAN E9 KY1-1104
Business Address C/O MAPLES CORPORATE SERVICES LIMITED UGLAND HOUSE, PO BOX 309 GRAND CAYMAN E9 KY1-1104 345-949-8066
Qiming Venture Partners VIII-HC, L.P. (Filed by) CIK: 0001910025 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G